Investor Presentaiton

PI EXTERNAL Business outlook remains robust.. Targeted expansion backed by solid growth visibility to support momentum Focus on new strategic initiatives to elevate performance P Inspired by Science Business outlook continues to be robust in FY22 supported by new launches and crop diversification Domestic : Focus on portfolio diversification with launch of novel offerings CSM Export: R&D focused approach to drive incremental business Efforts to drive strategic initiatives continues • • • • • • • 5 new launches in FY22, will strengthen rice, cotton and horticulture portfolio Crop diversification of existing products Rice, Horticulture, Cotton, Soybean and Wheat to drive growth Focus to expand application services business with an effort to provide wider solutions to farmers challenges 5-6 pipeline molecules at various stages of development to be commercialized in the coming FY Another MPP is planned to be made ready by Q2FY22, thus enhancing the overall capacities Order book continues to remain robust @ $1.5bn with high visibility of sustainable growth in the next 3-4 years Pursuing inorganic growth opportunities to diversify into adjacencies, widen technology portfolio and de-risk operations •Investing in a new R&D facility for deepening our technological capabilities, de-risking current operations and opening up newer opportunities • Actively evaluating select pharma assets and working with global consulting firm for crystallisation and successfully implementing strategic road map of diversification Amidst challenges owing to covid-19 and related uncertainties, we are confident of achieving >15% growth in FY22 and resolutely progressing on that path Q4 & FY21 Earnings Presentation 8

View entire presentation